Compendium of Cancer Genome Aberrations

Acute myeloid leukaemia with CBFB::MYH11 fusion

Revision as of 14:11, 3 November 2023 by Bailey.Glen (talk | contribs) (Created page with "{{DISPLAYTITLE:Acute myeloid leukaemia with CBFB::MYH11 fusion}} Haematolymphoid Tumours (5th ed.) {{Under Construction}} <blockquote class='bloc...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Haematolymphoid Tumours (5th ed.)

editHAEM5 Conversion Notes
This page was converted to the new template on 2023-11-03. The original page can be found at HAEM4:Acute Myeloid Leukemia (AML) with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11.

Primary Author(s)*

Christine Bryke, MD
Beth Israel Deaconess Medical Center, Boston, MA

Cancer Category/Type

Acute myeloid leukemia

Cancer Sub-Classification / Subtype

Acute myeloid leukaemia (AML) with inv(16)(p13.1q22) or t(16;16)(p13.1;q22) resulting in CBFB-MYH11 fusion

Definition / Description of Disease

Acute myeloid leukemia (AML) with inv(16)(p13.1q22) or t(16;16)(p13.1;q22) resulting in CBFB-MYH11 gene fusion is a subtype of AML with granulocytic and monocytic differentiation and abnormal bone marrow eosinophils. In the 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia, it is in the group of AML with recurrent genetic abnormalities[1]. In the older French-American-British (FAB) classification system, inv(16)(p13.1q22) or t(16;16)(p13.1;q22) positive AML belonged to the acute myelomonocytic leukemia with abnormal bone marrow eosinophils M4e category. inv(16)(p13.1q22) or t(16;16)(p13.1;q22) can occasionally be seen in therapy-related AML and in blast phase of chronic myelogenous leukemia. In those instances, the leukemia is not classified in the group of AML with recurrent genetic abnormalities due to clinical and prognostic differences.

  • inv(16)(p13.1q22), a pericentric inversion of chromosome 16, and the less common t(16;16)(p13.1;q22), a translocation involving the short arm of one chromosome 16 and the long arm of the other chromosome 16, define a distinctive cytogenetic subtype of acute myeloid leukemia. Both of these chromosome rearrangements result in the CBFB-MYH11 gene fusion.
  • Occurs in all age groups but predominantly in younger patients.
  • Myeloid sarcoma may be present at initial diagnosis or at relapse and in some patients may constitute the only evidence of relapse.
  • inv(16)(p13.1q22) is a subtle chromosome rearrangement that may not be appreciated when chromosome morphology is suboptimal.
  • Cases with a cryptic CBFB-MYH11 gene rearrangement are possible.
  • A deletion within 16p13 accompanying a rearrangement of 16p13 and 16q22 occurs in 20% of cases[2][3].
  • Loss of 3’ CBFB occurs in 4-8% of cases of CBFB rearranged AML. Of these cases, 69-73% are positive for CBFB-MYH11 fusion by RT-PCR [4][5][6][7].



 
t(16;16)(p13.1;q22)
 
inv(16)(p13.1q22)
 
inv(16)(p13.1q22). Courtesy of Karen Kundinger, Comprehensive Genetic Services, Milwaukee, WI

Synonyms / Terminology

Acute myeloid leukaemia (AML) with inv(16)(p13.1q22); AML, t(16;16)(p13.1;q22);AML,CBFB-MYH11; Acute myelomonocytic leukemia with abnormal eosinophils; FAB classification M4Eo

Epidemiology / Prevalence

Approximately 5-8% of AML cases have inv(16)(p13.1q22) or t(16;16)(p13.1;q22). More common in males and younger adults.

Clinical Features

Signs and Symptoms May present as myeloid sarcoma
Laboratory Findings Abnormal eosinophil component (bone marrow)

Leukocytosis

Sites of Involvement

Bone marrow

Morphologic Features

  • Bone marrow shows the usual morphologic features of acute myelomonocytic leukemia.
  • Eosinophils at all stages of maturation are usually increased.
  • Eosinophilic granules at the promyelocyte and myelocyte stages are larger than usual and often have a purple-violet color. They may be so dense as to obscure the nucleus.
  • Mature eosinophils may occasionally show nuclear hyposegmentation.
  • Abnormal eosinophils are not usually seen in the peripheral blood.
  • Auer rods may be present in myeloblasts.
  • Occasional cases do not have eosinophilia or exhibit only myeloid maturation without a monocytic component or only monocytic maturation.


 
Bone marrow aspirate with inv(16)(p13.1q22) positive myeloblasts and abnormal immature eosinophils (100X). Robert Willim, MD, Beth Israel Deaconess Medical Center, Boston, MA


Immunophenotype

  • Naphthol-ASD-chloroacetate esterase reaction, which is negative in normal eosinophils, is faintly positive in the abnormal eosinophils.
  • ≥3% of blasts show myeloperoxidase activity.
  • Monoblasts and promonoblasts usually show non-specific esterase activity.

Often a complex immunophenotype with multiple blast populations is seen in:

  • immature blasts with high CD34 and CD117 expression
  • populations with granulocytic differentiation positive for CD13, CD33, CD15, CD65 and MPO
  • populations with monocytic differentiation, positive for CD14, CD4, CD11c, CD11b, CD11c, CD64, CD36 and lysozyme
Finding Marker
Positive (granulocytic differentiation) CD13, CD33, CD15, CD65 and MPO
Positive (monocytic differentiation) CD14, CD4, CD11c, CD11b, CD11c, CD64, CD36 and lysozyme
Positive (subset)
Negative (universal)
Negative (subset)

Chromosomal Rearrangements (Gene Fusions)

Chromosomal Rearrangement Genes in Fusion (5’ or 3’ Segments) Pathogenic Derivative Prevalence Diagnostic Significance (Yes, No or Unknown) Prognostic Significance (Yes, No or Unknown) Therapeutic Significance (Yes, No or Unknown) Notes
inv(16)(p13.1q22) or t(16;16)(p13.1;q22) 5'CBFB / 3'MYH11 der(16) 5-8% of AML Yes Yes No Diagnostic
  • The presence of inv(16)(p13.1q22) or t(16;16)(p13.1;q22) is diagnostic of a cytogenetic subtype of AML with granulocytic and monocytic differentiation and abnormal bone marrow eosinophils.
  • When inv(16)(p13.1q22) or t(16;16)(p13.1;q22) are present the diagnosis of acute myeloid leukemia is made regardless of a blast count less than 20%.

Per 2022 International Consensus Classification of Myeloid Neoplasms and Acute Leukemias guidelines, blast count needs to be at least 10% or more [8]


Prognostic

  • inv(16)(p13.1q22) and t(16;16)(p13.1;q22) positive AML usually has a good response to chemotherapy and a high complete remission rate with long-term disease-free survival when treated with high dose cytarabine in the consolidation phase. Older age and KIT gene mutations adversely affected prognosis. The prognostic significance of other accompanying gene mutations is under investigation[9].
  • FLT3-TKD tyrosine kinase domain mutation and trisomy 8 are associated with a worse outcome.


Recent data demonstrate that the presence of kinase pathway variants (FLT3 (TKD and ITD), RAS, or KIT) or additional cytogenetic abnormalities (other than -Y) occurring in patients with CBF-rearranged AML treated with FLAG-based regimens was not an adverse prognostic factor [10].


Therapeutic target

  • AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22) currently has no molecular target for drug therapy.
  • Standard induction 7 + 3 chemotherapy regimen of cytarabine for 7 days plus an anthracycline or anthracenedione for 3 days. In first complete remission patients younger than 60 years without a KIT mutation are treated with at least three courses of high dose cytarabine. If a KIT mutation is present, bone marrow transplant is performed in first complete remission[11]. Other therapies under investigation include gemtuzumab ozogamicin, histone deacetylase inhibitors, DNA methyl transferase inhibitors, proteasome inhibition and tyrosine kinase inhibitors[12].

Individual Region Genomic Gain/Loss/LOH

inv(16)(p13.1q22) or t(16;16)(p13.1;q22) is the sole chromosome aberration in approximately 60% of cases.

Chr # Gain / Loss / Amp / LOH Minimal Region Genomic Coordinates [Genome Build] Minimal Region Cytoband Diagnostic Significance (Yes, No or Unknown) Prognostic Significance (Yes, No or Unknown) Therapeutic Significance (Yes, No or Unknown) Notes
8 Gain chr8:1-145,138,636 [hg38] chr8 No No No Frequently observed. Does not adversely affect the favorable prognosis associated with inv(16)(p13.1q22) or t(16;16)(p13.1;q22) unless a KIT gene mutation is also present (see below)
22 Gain chr22:1-50,818,468 [hg38] chr22 No No No Frequently observed. Does not adversely affect the favorable prognosis associated with inv(16)(p13.1q22) or t(16;16)(p13.1;q22) unless a KIT gene mutation is also present (see below)
21 Gain chr21:1-46,709,983 [hg38] chr21 No No No Occasionally observed. Does not adversely affect the favorable prognosis associated with inv(16)(p13.1q22) or t(16;16)(p13.1;q22) unless a KIT gene mutation is also present (see below)
7 Loss chr7:60,100,001-159,345,973 [hg38] chr7q No No No Occasionally observed. Does not adversely affect the favorable prognosis associated with inv(16)(p13.1q22) or t(16;16)(p13.1;q22) unless a KIT gene mutation is also present (see below)

Characteristic Chromosomal Patterns

Put your text here (EXAMPLE PATTERNS: hyperdiploid; gain of odd number chromosomes including typically chromosome 1, 3, 5, 7, 11, and 17; co-deletion of 1p and 19q; complex karyotypes without characteristic genetic findings; chromothripsis)

Chromosomal Pattern Diagnostic Significance (Yes, No or Unknown) Prognostic Significance (Yes, No or Unknown) Therapeutic Significance (Yes, No or Unknown) Notes
EXAMPLE

Co-deletion of 1p and 18q

Yes No No EXAMPLE:

See chromosomal rearrangements table as this pattern is due to an unbalanced derivative translocation associated with oligodendroglioma (add reference).

editv4:Characteristic Chromosomal Patterns
The content below was from the previous version of the page. Please incorporate above.
Chromosomal Pattern Diagnostic Significance (Yes, No or Unknown) Prognostic Significance (Yes, No or Unknown) Therapeutic Significance (Yes, No or Unknown) Notes
Not Applicable N/A N/A N/A N/A

Gene Mutations (SNV/INDEL)

AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22) has genetic heterogeneity at the molecular level. Several genes have been identified that are frequently mutated in this subset of AML, some of them adversely affecting prognosis.

Gene; Genetic Alteration Presumed Mechanism (Tumor Suppressor Gene [TSG] / Oncogene / Other) Prevalence (COSMIC / TCGA / Other) Concomitant Mutations Mutually Exclusive Mutations Diagnostic Significance (Yes, No or Unknown) Prognostic Significance (Yes, No or Unknown) Therapeutic Significance (Yes, No or Unknown) Notes
KIT; Gain of Function mutations in exons 8 or 17 Proto-Oncogene 30%[9] N/A N/A No Yes The KIT gene on 4q12 encodes a transmembrane glycoprotein that activates signaling pathways involved in cellular proliferation, differentiation and survival. Associated with a high risk of relapse in cases of AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22). Patients with KIT mutations have a significantly shorter overall survival and disease free survival periods than those without KIT mutations. Gene expression profile analysis of KIT mutation positive core binding factor AML showed dysregulation of genes belonging to the NF-κB signaling complex indicating impairment of apoptosis[12].

Other Mutations

Mutations in NRAS (45%), KRAS and FLT3 (FLT3-TKD and FLT3-ITD) have also been found in inv(16)(p13.1q22) or t(16;16)(p13.1;q22) AML[13]. Recently a FLT3 N676K mutation has been identified in a small subset of the disease[14][15]. In addition, TET2 mutations have been identified[16] and WT1 mutations have been found to be relatively common (13.8%) in inv(16) core-binding factor leukemia[17]. CBL mutations are less common and can be seen in ~5% of patients with inv(16) AML[18].

  • Negative for ASXL2 mutation [which is common in t(8;21)].

Note: A more extensive list of mutations can be found in cBioportal (https://www.cbioportal.org/), COSMIC (https://cancer.sanger.ac.uk/cosmic), ICGC (https://dcc.icgc.org/) and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.

Epigenomic Alterations

None

Genes and Main Pathways Involved

Put your text here and fill in the table (Instructions: Can include references in the table.)

Gene; Genetic Alteration Pathway Pathophysiologic Outcome
EXAMPLE: BRAF and MAP2K1; Activating mutations EXAMPLE: MAPK signaling EXAMPLE: Increased cell growth and proliferation
EXAMPLE: CDKN2A; Inactivating mutations EXAMPLE: Cell cycle regulation EXAMPLE: Unregulated cell division
EXAMPLE:  KMT2C and ARID1A; Inactivating mutations EXAMPLE:  Histone modification, chromatin remodeling EXAMPLE:  Abnormal gene expression program
editv4:Genes and Main Pathways Involved
The content below was from the previous version of the page. Please incorporate above.

CBFB (core binding factor β) on 16q22 is transcribed from centromere to telomere. It codes for CBFβ, a subunit of the transcription factor complex core binding factor. CBFβ by itself does not contain any DNA binding motif or transcriptional activation domain, but forms a dimer with CBFa (RUNX1) which is a transcription factor . MYH11 (smooth muscle myosin heavy-chain gene) on 16p13.1 is transcribed from centromere to telomere, contains a N-term ATPase head responsible for actin binding and mechanical movement, and a C-terminus long repeat of coil-coil domain to facilitate filament aggregates; member of the myosin II family.


DNA: inv(16)(p13.1q22) and t(16;16)(p13.1;q22) result in the CBFB-MYH11 hybrid gene involving fusion of 5’ CBFB in intron 5 and variable breakpoints in MYH11.


mRNA: At least 8 different CBFB-MYH11 fusion transcripts have been described. A transcript with CBFB and MYH11 positions at nucleotides 495 and 1921, respectively, is found in about 90% of patients. There is no reciprocal MYH11-CBFB transcript.


Protein: A fusion protein with the first 165 (or 133 in a few cases) amino acids of the N-terminus of CBFβ, minus only 17 or 22 amino acids, fused to the tail of the MYH11 C-terminus with its multimerization domain. The breakpoint in MYH11 is variable. The fusion protein retains the ability to dimerize with RUNX1 in the heterodimeric core binding factor. The core binding factor is a transcription factor that plays an essential role in regulation of normal hematopoiesis. It is composed of a DNA-binding CBFα (RUNX1) chain and a non-DNA-binding CBFβ chain. It is likely oncogenic due to altered transcriptional regulation of normal RUNX1 target genes. Animal studies suggest that the fusion proteins alone are not able to induce leukemia and that additional genetic alterations are required for leukemogenic transformation[19].

Genetic Diagnostic Testing Methods

Chromosome analysis for inversion or translocation; FISH or RT-PCR for CBFB-MYH11 gene fusion rearrangement.

FISH or RT-PCR for CBFB-MYH11 is needed when chromosome morphology is suboptimal and for cytogenetically cryptic cases with typical bone marrow morphology and immunophenotype.


 
FISH with CBFB break apart probe set on interphase cells with inv(16)(p13.1q22). Craig Kanaugh, Comprehensive Genetic Services,Milwaukee, WI.


  • RT-PCR for CBFB-MYH11 is employed for minimal residual disease detection. The attainment of optimal PCR response (OPR) of <0.1% PCR transcripts (at a level of detection of 10-4 ) after induction (C1) and <0.01% during or following consolidation has led to improved relapse-free survival (RFS)[20][21]
  • In KIT mutation positive cases detection of the KIT mutation should not be used for assessment minimal residual disease because KIT mutations are frequently lost at relapse[18].

Familial Forms

None

Additional Information

None

Links

CBFB

MYH11

http://www.uptodate.com/contents/cytogenetics-in-acute-myeloid-leukemia
http://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=HGNC:1539

http://www.clevelandclinicmeded.com.

References

  1. ↑ Arber, Daniel A.; et al. (05 19, 2016). "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia". Blood. 127 (20): 2391–2405. doi:10.1182/blood-2016-03-643544. ISSN 1528-0020. PMID 27069254. Check date values in: |date= (help)
  2. ↑ Marlton, P.; et al. (1995-02-01). "Molecular characterization of 16p deletions associated with inversion 16 defines the critical fusion for leukemogenesis". Blood. 85 (3): 772–779. ISSN 0006-4971. PMID 7833479.
  3. ↑ Martinet, D.; et al. (1997-07). "Detection of 16 p deletions by FISH in patients with inv(16) or t(16;16) and acute myeloid leukemia (AML)". Leukemia. 11 (7): 964–970. doi:10.1038/sj.leu.2400681. ISSN 0887-6924. PMID 9204976. Check date values in: |date= (help)
  4. ↑ Yang, Richard K.; et al. (2021-10-26). "CBFB Break-Apart FISH Testing: An Analysis of 1629 AML Cases with a Focus on Atypical Findings and Their Implications in Clinical Diagnosis and Management". Cancers. 13 (21): 5354. doi:10.3390/cancers13215354. ISSN 2072-6694. PMC 8582369 Check |pmc= value (help). PMID 34771519 Check |pmid= value (help).
  5. ↑ Lv, Lili; et al. (2020). "Acute myeloid leukemia with inv(16)(p13.1q22) and deletion of the 5'MYH11/3'CBFB gene fusion: a report of two cases and literature review". Molecular Cytogenetics. 13: 4. doi:10.1186/s13039-020-0474-9. ISSN 1755-8166. PMC 6990480. PMID 32015759 Check |pmid= value (help).
  6. ↑ Kelly, Johanna; et al. (2005-10-15). "3'CBFbeta deletion associated with inv(16) in acute myeloid leukemia". Cancer Genetics and Cytogenetics. 162 (2): 122–126. doi:10.1016/j.cancergencyto.2005.03.001. ISSN 0165-4608. PMID 16213359.
  7. ↑ Tang, Guilin; et al. (2022-04). "3'CBFB deletion in CBFB-rearranged acute myeloid leukemia retains morphological features associated with inv(16), but patients have higher risk of relapse and may require stem cell transplant". Annals of Hematology. 101 (4): 847–854. doi:10.1007/s00277-022-04767-1. ISSN 1432-0584. PMID 35184217 Check |pmid= value (help). Check date values in: |date= (help)
  8. ↑ Arber, Daniel A.; et al. (2022-09-15). "International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data". Blood. 140 (11): 1200–1228. doi:10.1182/blood.2022015850. ISSN 0006-4971. PMC PMC9479031 Check |pmc= value (help). PMID 35767897 Check |pmid= value (help).CS1 maint: PMC format (link)
  9. ↑ 9.0 9.1 Paschka, Peter; et al. (2006-08-20). "Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study". Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 24 (24): 3904–3911. doi:10.1200/JCO.2006.06.9500. ISSN 1527-7755. PMID 16921041.
  10. ↑ Senapati, Jayastu; et al. (2023-03). "Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G‐CSF based regimens". American Journal of Hematology. 98 (3). doi:10.1002/ajh.26811. ISSN 0361-8609. Check date values in: |date= (help)
  11. ↑ Yoon, J.-H.; et al. (2014-12). "Identification of molecular and cytogenetic risk factors for unfavorable core-binding factor-positive adult AML with post-remission treatment outcome analysis including transplantation". Bone Marrow Transplantation. 49 (12): 1466–1474. doi:10.1038/bmt.2014.180. ISSN 1476-5365. PMID 25111512. Check date values in: |date= (help)
  12. ↑ 12.0 12.1 Solh, Melhem; et al. (2014-12). "Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy". American Journal of Hematology. 89 (12): 1121–1131. doi:10.1002/ajh.23821. ISSN 1096-8652. PMID 25088818. Check date values in: |date= (help)
  13. ↑ Paschka, Peter; et al. (2013-01-03). "Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG)". Blood. 121 (1): 170–177. doi:10.1182/blood-2012-05-431486. ISSN 1528-0020. PMID 23115274.
  14. ↑ Opatz, Sabrina; et al. (2013-09-05). "Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia". Blood. 122 (10): 1761–1769. doi:10.1182/blood-2013-01-476473. ISSN 1528-0020. PMID 23878140.
  15. ↑ Huang, Kezhi; et al. (2016-04). "Leukemogenic potency of the novel FLT3-N676K mutant". Annals of Hematology. 95 (5): 783–791. doi:10.1007/s00277-016-2616-z. ISSN 1432-0584. PMID 26891877. Check date values in: |date= (help)
  16. ↑ Cher, C. Y.; et al. (07 08, 2016). "Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome". Blood Cancer Journal. 6 (7): e442. doi:10.1038/bcj.2016.51. ISSN 2044-5385. PMC 5030377. PMID 27391574. Check date values in: |date= (help)
  17. ↑ Park, Sang Hyuk; et al. (2015-05). "Incidences and Prognostic Impact of c-KIT, WT1, CEBPA, and CBL Mutations, and Mutations Associated With Epigenetic Modification in Core Binding Factor Acute Myeloid Leukemia: A Multicenter Study in a Korean Population". Annals of Laboratory Medicine. 35 (3): 288–297. doi:10.3343/alm.2015.35.3.288. ISSN 2234-3814. PMC 4390696. PMID 25932436. Check date values in: |date= (help)
  18. ↑ 18.0 18.1 Allen, C.; et al. (2013-09). "The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia". Leukemia. 27 (9): 1891–1901. doi:10.1038/leu.2013.186. ISSN 1476-5551. PMID 23783394. Check date values in: |date= (help)
  19. ↑ Downing, James R. (2003-02). "The core-binding factor leukemias: lessons learned from murine models". Current Opinion in Genetics & Development. 13 (1): 48–54. doi:10.1016/s0959-437x(02)00018-7. ISSN 0959-437X. PMID 12573435. Check date values in: |date= (help)
  20. ↑ Boddu, Prajwal; et al. (2018-06-08). "Response kinetics and factors predicting survival in core-binding factor leukemia". Leukemia. 32 (12): 2698–2701. doi:10.1038/s41375-018-0158-1. ISSN 0887-6924.
  21. ↑ Yin, John A. Liu; et al. (2012-10-04). "Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial". Blood. 120 (14): 2826–2835. doi:10.1182/blood-2012-06-435669. ISSN 0006-4971.

Notes

*Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome.








Edited by: Fabiola Quintero-Rivera 7/21/2018


*Citation of this Page: “Acute myeloid leukaemia with CBFB::MYH11 fusion”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated 11/3/2023, https://ccga.io/index.php/HAEM5:Acute_myeloid_leukaemia_with_CBFB::MYH11_fusion.

Retrieved from "https://ccga.io/index.php?title=HAEM5:Acute_myeloid_leukaemia_with_CBFB::MYH11_fusion&oldid=12827"